Inhibiting angiogenesis by targeting specific pro-angiogenic factors such as VEGF has become a major focus of drug development for diabetic retinopathy, and anti-VEGF drugs are used to treat diabetic retinopathy [25], [26]. This evidence concerns the gene VEGFA and diabetic retinopathy.